Efficacy and Safety of Corticosteroids in Tuberculous Meningitis: Systematic Review, Meta-Analysis and Meta-Regression
Ayesha Younas1, Muhammad Talha Shaukat2, Rizwana Noor3, Irra Tariq4, Muhammad Sameer Almas1, Maryam Mirza5, Lamiya Pirzada5, Norma Nicole Gamarra Valverde6, Mifrah Rahat Khan Sherwani7, Rosheen Jamil2, Mahwash Siddiqi8
1Medicine, Allama Iqbal Medical College, 2Medicine, King Edward Medical University, 3Medicine, Khyber Medical College, 4Medicine, United Medical and Dental College, 5Medicine, Jinnah Sindh Medical University, 6Universidad Peruana Cayetano Heredia, 7Medicine, Karachi Medical and Dental College, 8Medicine, Penn State Health Milton S. Hershey Medical Center
Objective:
To evaluate the efficacy and safety of adjunctive corticosteroid therapy in patients with Tuberculous Meningitis (TBM) with an emphasis on treatment duration, patient subgroups, and outcomes across different geographical settings.
Background:
The effectiveness in clinical outcomes following corticosteroid therapy in patients with TBM was still unknown. Therefore, we performed a systematic review and meta-analysis to assess the role of adjunctive corticosteroid therapy in patients with TBM.
Design/Methods:
PubMed, Google Scholar, Cochrane Library, Clinical Trials.gov, Scopus, and Embase were thoroughly searched. The standard of the included trials was evaluated using the Cochrane Risk of Bias tool. With statistical significance set at P<0.05, pooled risk ratios (RR) and their corresponding 95% confidence intervals have been calculated using RevMan version 5.4.1.
Results:
Eleven studies consisting of 1917 patients out of which 985 patients were given corticosteroids therapy. The results showed that there was significant reduction in mortality (RR = 0.84, 95% CI: 0.76–0.94, P = 0.002) and heterogeneity (I= 0%). Subgroup analysis was also performed which also showed benefits of dexamethasone use (RR = 0.87, CI: 0.77–0.97) in low income countries (RR = 0.82, CI: 0.72–0.95). However, in HIV-positive patients, corticosteroids therapy did not show reduction in mortality and was not associated with statistically significant adverse effects including gastrointestinal bleeding, visual impairment, auditory impairment, hydrocephalus or joint disorders.
Conclusions:
In HIV-negative TBM patients, especially those in resource limited regions, adjunctive corticosteroid therapy particularly dexamethasone improved all-cause mortality when administered for <9 months. Adverse effects such as hydrocephalus and hepatobiliary diseases were also observed, requiring more multi-centered randomized controlled trials for evaluating the ideal duration of dexamethasone therapy, and its effects in HIV-positive patients.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.